[1]
Chang, A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer, 2011, 71(1), 3-10.
[2]
Weaver, K.E.; Rowland, J.H.; Alfano, C.M.; Mcneel, T.S. Parental cancer and the family: A population-based estimate of the number of US cancer survivors residing with their minor children. Cancer, 2010, 116(18), 4395-4401.
[3]
Chandarana, S.P.; Lee, J.S.; Chanowski, E.J.P.; Sacco, A.G.; Bradford, C.R.; Wolf, G.T.; Prince, M.E.; Moyer, J.S.; Avraham, E.; Worden, F.P. Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer. Head Neck, 2013, 35(8), 1083-1090.
[4]
Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New . Eng. J. Med., 2004, 350(350), 2129-2139.
[5]
Phuchareon, J.; Mccormick, F.; Eisele, D.W.; Tetsu, O. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc. Natl. Acad. Sci. USA, 2015, 112(29), E3855.
[6]
Wakeling, A.E.; Guy, S.P.; Woodburn, J.R.; Ashton, S.E.; Curry, B.J.; Barker, A.J.; Gibson, K.H. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res., 2002, 62(20), 5749-5754.
[7]
Higgins, G.S.; Krause, M.; Mckenna, W.G.; Baumann, M. Personalized radiation oncology: Epidermal growth factor receptor and other receptor tyrosine kinase inhibitors. Rec Result Cancer Res., 2016, 198, 107-122.
[8]
Barbieri, F.; Würth, R.; Favoni, R.E.; Pattarozzi, A.; Gatti, M.; Ratto, A.; Ferrari, A.; Bajetto, A.; Florio, T. Receptor tyrosine kinase inhibitors and cytotoxic drugs affect pleural mesothelioma cell proliferation: Insight into EGFR and ERK1/2 as antitumor targets. Biochem. Pharmacol., 2011, 82(10), 1467-1477.
[9]
Jung, M.; Cho, B.C.; Lee, C.H.; Park, H.S.; Kang, Y.A.; Kim, S.K.; Chang, J.; Kim, D.J.; Sun, Y.R.; Kim, J.H. EGFR Polymorphism as a Predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI. Yonsei Med. J., 2012, 53(6), 1128-1135.
[10]
De, R.M.; Loiacono, L.; Fusilli, C.; Poeta, M.L.; Mazza, T.; Sanchez, M.; Marchionni, L.; Signori, E.; Lamorte, G.; Vescovi, A.L. Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly Associates with Poor Prognosis in Colorectal Cancer. Clin. Cancer Res., 2017, 23(1), 159-170.
[11]
Wheler, J.J. Combining erlotinib and cetuximab is associated with activity in patients with non-small cell lung cancer (including squamous cell carcinomas) and wild-type EGFR or resistant mutations. Mol. Cancer Therapeut., 2013, 12(10), 2167-2175.
[12]
Schilder, R.J.; Sill, M.W.; Chen, X.; Darcy, K.M.; Decesare, S.L.; Lewandowski, G.; Lee, R.B.; Arciero, C.A.; Wu, H.; Godwin, A.K. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: A Gynecologic Oncology Group Study. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res., 2005, 11(15), 5539-5548.
[13]
Abu-Yousif, A.O.; Moor, A.C.E.; Zheng, X.; Savellano, M.D.; Yu, W.; Selbo, P.K.; Hasan, T. Epidermal growth factor receptor-targeted photosensitizer selectively inhibits EGFR signaling and induces targeted phototoxicity in ovarian cancer cells. Cancer Lett., 2012, 321(2), 120-127.
[14]
Yang, J.C.; Hirsh, V.; Schuler, M.; Yamamoto, N.; O’Byrne, K.J.; Mok, T.S.; Zazulina, V.; Shahidi, M.; Lungershausen, J.; Massey, D. Symptom control and quality of life in LUX-Lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J. Clin. Oncol., 2013, 31(27), 3342-3350.
[15]
Ruebner, R.; Goldberg, D.; Abt, P.L.; Bahirwani, R.; Levine, M.; Sawinski, D.; Bloom, R.D.; Reese, P.P. Risk of end-stage renal disease among liver transplant recipients with pretransplant renal dysfunction. Am. J. Transplant., 2012, 12(11), 2958.
[16]
Yang, C.H.; Shih, J.Y.; Su, W.C.; Hsia, T.C.; Tsai, C.M.; Ou, S.H.I.; Yu, C.J.; Chang, G.C.; Ho, C.L.; Sequist, L.V. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial. Lancet Oncol., 2012, 13(5), 539-548.
[17]
Thongprasert, S. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. J. Evid. Based Med., 2011, 361(10), 947-957.
[18]
Sequist, L.V.; Martins, R.G.; Spigel, D.; Grunberg, S.M.; Spira, A.; Jänne, P.A.; Joshi, V.A.; Mccollum, D.; Evans, T.L.; Muzikansky, A. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J. Clinic. Oncol. Official J. Am. Soc. Clin. Oncol., 2008, 26(15), 2442-2449.
[19]
Pao, W.; Ladanyi, M.; Miller, V.A.; Group, L.C.O. Erlotinib in lung cancer. New. Engl. J. Med., 2005, 353(16), 1739-1741.
[20]
Sequist, L.V.; Yang, J.C.; Yamamoto, N.; Obyrne, K.; Hirsh, V.; Mok, T.; Geater, S.L.; Orlov, S.; Tsai, C.M.; Boyer, M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J. Clin. Oncol., 2013, 31(27), 3327-3334.
[21]
Xu, Z.; Ting, P.; Xun, J.; Jian, L.; Linjiang, T.; Zeng, L.; Wei, Y.; Yungen, X.; Mengyuan, L.; Jian, D. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor. Bioorgan. Med. Chem., 2013, 21(24), 7988-7998.
[22]
Yu-Jing, Y.J.; Zhang, C.M.; Liu, Z.P. Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds. Anticancer. Agents Med. Chem., 2012, 12(4), 391-406.
[23]
Mendel, D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, G.; Schreck, R.E.; Abrams, T.J.; Ngai, T.J.; Lee, L.B. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/ pharmacodynamic relationship. Clin. Cancer Res. Off. J. Am. Associat. Cancer Res., 2003, 9(1), 327-337.
[24]
Motzer, R.J.; Rini, B.I.; Bukowski, R.M.; Curti, B.D.; George, D.J.; Hudes, G.R.; Redman, B.G.; Margolin, K.A.; Merchan, J.R.; Wilding, G. Sunitinib in patients with metastatic renal cell carcinoma. Yearbook Urol., 2006, 295(21), 2516-2524.
[25]
Socinski, M.A.; Novello, S.; Brahmer, J.R.; Rosell, R.; Sanchez, J.M.; Belani, C.P.; Govindan, R.; Atkins, J.N.; Gillenwater, H.H.; Pallares, C. Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non-Small-Cell Lung Cancer. J. Clin. Oncol., 2008, 26(4), 650-656.
[26]
Yu, Z.; Li, X.M.; Liu, S.H.; Liu, B.; Gao, C.H.; Hou, X. Downregulation of both EGFR and ErbB3 improves the cellular response to pemetrexed in an established pemetrexed-resistant lung adenocarcinoma A549 cell line. Oncol. Rep., 2014, 31(4), 1818-1824.
[27]
Li, X.; Lv, Y.; Yuan, A.; Yi, S.; Ma, Y.; Li, Z. Gastrin-releasing peptide promotes the growth of HepG2 cells via EGFR-independent ERK1/2 activation. Oncol. Rep., 2010, 24(2), 441-448.
[28]
Garcia, R.; Franklin, R.A.; Mccubrey, J.A. Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of other growth factors. Cell Cycle, 2006, 5(16), 1840-1846.
[29]
Kim, J.H.; Xu, C.; Keum, Y.S.; Reddy, B.; Conney, A.; Kong, A.N. Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin. Carcinogenesis, 2006, 27(3), 475-482.
[30]
Tu, Y.; Ouyang, Y.; Xu, S.; Zhu, Y.; Li, G.; Sun, C.; Zheng, P.; Zhu, W. Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors. Bioorg. Med. Chem., 2016, 24(7), 1495-1503.